A successful desensitization in an adult patient with ARA-C infusion reaction

J Oncol Pharm Pract. 2024 Jun;30(4):780-782. doi: 10.1177/10781552241242691. Epub 2024 Mar 28.

Abstract

Introduction: Cytarabine (ARA-C) is an antimetabolite agent used especially in the treatment of hematologic malignancies. Infusion reactions have an important place among the side effects that may occur due to treatment. Clinical findings of infusion reactions resemble allergic reactions.

Case report: 47-year-old male patient with a diagnosis of B-cell Acute Lymphoblastic Leukaemia developed infusion reaction during ARA-C treatment.

Management & outcome: There was no alternative treatment option for his existing malignant disease, we decided ARA-C desensitization.

Discussion: We would like to describe a successful desensitization protocol in an adult patient who experienced a reaction during ARA-C infusion.

Keywords: ARA-C; Drug allergy; cytarabine; desensitization.

Publication types

  • Case Reports

MeSH terms

  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / adverse effects
  • Cytarabine* / administration & dosage
  • Cytarabine* / adverse effects
  • Desensitization, Immunologic* / methods
  • Drug Hypersensitivity* / etiology
  • Drug Hypersensitivity* / therapy
  • Humans
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology

Substances

  • Cytarabine
  • Antimetabolites, Antineoplastic